Automated and Objective Assessments of Radiation-Induced Fibrosis Using Advanced Ultrasound Imaging in Breast Cancer Radiation Therapy
J. Zhou,G. J. Kutcher,S. A. Woodhouse,P. B. Schiff,L. Ballas,W. Vance,P. Zhang,Z. Lu,E. Pile-Spellman,T. Liu
DOI: https://doi.org/10.1016/j.ijrobp.2008.06.1639
2008-01-01
Abstract:Purpose/Objective(s)We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program.Materials/MethodsTwenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference.ResultsThe ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique.ConclusionsWe have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites. Purpose/Objective(s)We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program. We have recently reported that ultrasound imaging together with ultrasound tissue characterization (UTC) can provide quantitative assessment of radiation-induced tissue toxicity (ASTRO and RSNA 2007). Specifically, an UTC parameter, midband-fit (MBF), correlates with the presence of soft-tissue fibrosis. We now report an automated-tissue-toxicity-assessment (ATTA) program to evaluate radiation-induced fibrosis in the clinic. This study evaluates the performance of our ATTA program. Materials/MethodsTwenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference. Twenty-three breast cancer patients previously treated with surgery and radiation therapy were recruited and analyzed. Ultrasound B-mode images and radio-frequency data were acquired from both treated and untreated (contralateral) breasts. For fibrosis evaluation, the ATTA program calculates the MBF within a pre-defined region-of-interest of irradiated glandular tissue for each patient. The MBF measures the spectral intensity of the backscattered ultrasound signal and increases with tissue collagen proliferation; it can therefore be used to measure fibrosis. To verify the ATTA program, we compared the ATTA results to a physician-performed manual toxicity measurement on each ultrasound image. An intra-class correlation coefficient (ICC) was used to calculate the correlation between the two methods. To evaluate the reliability of the ATTA in assessing fibrosis, a paired t test for the MBF of the treated and the untreated breast was used. The patients' self-assessments of breast hardening (fibrosis) were used as reference. ResultsThe ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique. The ICC demonstrates a substantial agreement between the ATTA and the manual method (0.90). Paired t tests of the MBF difference between the treated and the untreated breasts are 2.43 dB (95% CI, 1.17 dB ∼ 3.69 dB, p < 0.001) and 2.07 dB (95% CI, 1.30 dB ∼ 2.83 dB, p < 0.001) for using the ATTA and the manual measurement, respectively. The paired t tests confirm a significant difference of the MBF between the treated and the untreated breast. The median value of the MBF difference in each group increases proportionally with the patient self-assessment scale. The concordance between the ATTA evaluations and the patients' self-assessments demonstrate the reliability of this ultrasound technique. ConclusionsWe have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites. We have developed an advanced ultrasonic technology to evaluate radiation-induced fibrosis in breast cancer radiation therapy. This technique is non-invasive and reliable, and provides an objective and quantitative measurement of late tissue toxicity. Although first clinically applied in breast radiotherapy, our ATTA program of fibrosis evaluation will also be valuable for evaluating tissue toxicity in other treatment sites.